If you add this to the diabetic medication you were taking, it's going to
Feb 22, 2025
|
Dapagliflozin is an oral diabetes treatment. SGLT-2 inhibitor drug reduces blood sugar by inhibiting the reabsorption of glucose from the kidneys and draining it into the urine.
A research team led by Professor Jeong In-kyung at Gangdong Kyunghee University Hospital confirmed that adding dapagliflozin to the commonly used evogliptin (DPP-4 inhibitor) and metformin (insulin sensitivity amelioration agent) further reduced glycated hemoglobin levels and further reduced average weight.
The study was conducted on a total of 198 patients with type 2 diabetes. We divided into two groups and closely monitored the effects on patients' blood sugar, weight, liver health indicators, and metabolic health for 24 weeks after additional dapagliflozin 10 mg or placebo was taken to conventional treatment.
The results of the study were very positive. Patients who took additional dapagliflozin had an average reduction in glycated hemoglobin (HbA1c) levels of 0.7%. This can make a big difference in blood sugar management. Average weight was reduced by 1.79 kg, which also reduced the risk of obesity-related complications, and liver health indicators and insulin resistance indices were also significantly improved, which had a positive effect on metabolic health. The incidence of side effects was not significantly different from that of the placebo group, and the risk of hypoglycemia was also low.
In the early 1990s, there were only two types of diabetes drugs available in Korea, but now a total of nine drugs have been developed and used. △Improved insulin resistance △Improved insulin secretion △Increased appetite suppression △Block glucose absorption from the intestine △Promoted glucose excretion into the kidneys △Increased creatine hormones have been developed, enabling customized prescriptions according to patient conditions.
Professor Jeong In-kyung Jeong confirmed that the additional administration of an SGLT-2 inhibitor called dapagliflozin to conventional treatments is effective not only in controlling blood sugar, but also in weight loss and metabolism improvement. It will be a good option for patients because it has few side effects and is convenient to use." In addition to blood sugar loss and weight loss, SGLT-2 inhibitors have many advantages, such as reducing blood pressure, improving proteinuria, protecting the kidneys, reducing the risk of heart failure, and reducing mortality from heart disease, as well as glucose excretion into the kidneys.
According to the 「Diabetes Fact Sheet 2024」 published by the Korean Diabetes Association in October last year, the prevalence of diabetes in the 30s and older in Korea was 14.8% as of 2022, with about 5.33 million people suffering from diabetes. Diabetes is scary because it not only damages the eyes, kidneys, and nerves, but also brain and cardiovascular blood vessels are associated with various complications. The problem is that all of these complications from diabetes occur when blood sugar is not controlled, and the longer the duration of diabetes.
In addition to improving blood sugar, SGLT-2 inhibitors such as dapagliflozin are drugs that have been proven to have protective effects against weight loss, blood pressure loss, kidney and heart. Recently, as the number of obese young diabetic patients increases, they are attracting more attention, and there are high expectations for a decrease in complications of diabetic patients. However, when you take the medicine for the first time, you often drink water because you have symptoms of thirst or frequent urination, and these symptoms disappear over time. In addition, cystitis or genital infections can rarely occur, so it is recommended to thoroughly hygiene.
|
This article was translated by Naver AI translator.
